Your timeline is way off. I wonder how many sharepoint collaboration sites get off the ground each month : )
------------
Steve Worsley .. .. Vice President Business Development Peregrine Pharmaceuticals November 2013 – Present (2 years 9 months)Greater Los Angeles Area
(a $255MM biopharmaceutical focused on immuno-oncology mAbs (Phase 3 NSCLC, MBC) Responsible for all business development with top 20 pharmaceutical and biotech companies. Primary focus has been in the development and execution of five-year strategic business plan focused on worldwide licensing strategy for our Phase III mAb; Bavituximab and in-licensing of key assets. Also lead for all licensing long-term alliance strategies for our Immuno Oncology collaborations with leading pharma’s and institutes. • Negotiated/finalized Peregrines’ key research agreement w/Jedd Wolchok’s Lab at Memorial Sloan Kettering Cancer Center MSKCC for studies involving the combination of bavituximab with PD-1/L1 inhibitors • Negotiated/finalized clinical agreement w/Astra Zeneca/MedImmune for NSCLC studies involving the combination of bavituximab with PD-L1 inhibitor: Durvalumab. Followed by 2nd contract 3 months later for add’l clinical combination studies. • Negotiated/finalized research license and option agreement w/Affitech - for pre-clinical VEGF targeting mAbs (2014)
Market Data 
Markets 
AI
